nNNPDF2.0:quark flavor separation in nuclei from LHC data

We present a model-independent determination of the nuclear parton distribution functions (nPDFs) using machine learning methods and Monte Carlo techniques based on the NNPDF framework. The neutral-current deep-inelastic nuclear structure functions used in our previous analysis, nNNPDF1.0, are complemented by inclusive and charm-tagged cross-sections from charged-current scattering. Furthermore, we include all available measurements of W and Z leptonic rapidity distributions in proton-lead collisions from ATLAS and CMS at s = 5.02 TeV and 8.16 TeV. The resulting nPDF determination, nNNPDF2.0, achieves a good description of all datasets. In addition to quantifying the nuclear modifications affecting individual quarks and antiquarks, we examine the implications for strangeness, assess the role that the momentum and valence sum rules play in nPDF extractions, and present predictions for representative phenomenological applications. Our results, made available via the LHAPDF library, highlight the potential of high-energy collider measurements to probe nuclear dynamics in a robust manner

The Impact of Carbohydrate and Protein Level and Sources on Swine Manure Foaming Properties

This study explored the impact of swine diet on the composition, methane production potential, and foaming properties of manure. Samples of swine manure were collected from controlled feeding trials with diets varying in protein and carbohydrate levels and sources. Protein sources consisted of corn with amino acids, corn-soybean meal with amino acids, corn-soybean meal, corn-canola meal, corn-corn gluten meal, and corn-poultry meal. Carbohydrate sources consisted of corn-soybean meal, barley, beet pulp, distillers dried grains with solubles (DDGS), soy hulls, and wheat bran. Manure samples were tested for a number of physical and biochemical parameters, including total solids, volatile solids, viscosity, density, methane production rate, biochemical methane potential, foaming capacity, and foam stability. Statistical analyses were performed to evaluate whether different carbohydrate and/or protein ingredients affected these physico-chemical properties or the samples’ ability to produce methane gas. After conducting these trials, another feeding trial was performed to evaluate if the addition of Narasin into rations (corn-soybean and DDGS) could reduce the methane production rate or potential of the manure. These samples were also tested for the physical and biochemical parameters mentioned previously. Finally, an additional manure foaming study was conducted involving the addition of specific carbohydrates ground to different particle sizes and corn oil to observe the effects that the additives had on foaming capacity and stability

Three-Phase Foam Analysis and the Development of a Lab-Scale Foaming Capacity and Stability Test for Swine Manures

Foam accumulation on the manure slurry at deep pit swine facilities has been linked to flash fire incidents, making it a serious safety concern for pork producers. In order to investigate this phenomenon, samples of swine manure were collected from over 50 swine production facilities in Iowa with varying levels of foam accumulation over a seven month period. These samples were tested for a number of physical and chemical parameters including temperature, pH, total solids, volatile solids, volatile fatty acid concentration, biochemical methane potential, and methane production rate. After establishing these parameters, a foaming capacity and stability test was performed where samples were placed in clear PVC tubes with air diffusers at the bottom to simulate biogas production. The amount of foam produced at a set aeration rate was recorded as a measure of foaming capacity, and foam stability was assessed by measuring the height of foam remaining at certain time intervals after aeration had ceased. The results of this test indicated that samples collected from foaming barns showed a greater capacity to produce and stabilize foam. In addition, statistical analysis indicated that manures with foam produced methane at significantly greater rates than non-foaming manures (0.154 ± 0.010 and 0.052 ± 0.003 L CH4./L slurry*day respectively, average standard error), and consequently had significantly greater fluxes of methane moving through the manure volume. On the other hand, the biochemical methane production assay suggested that manure from foaming pits had less potential to generate methane (112 ± 9 mL CH4/g VS) than non-foaming pits (129 ± 9 mL CH4/g VS), and the VFA analysis showed significantly lower concentrations in foaming pits (4472, 3486, and 1439 μg/g for the surface level and descending depths of the pit, respectively) as compared to non-foaming pits (9385,8931, and 6938 μg/g for the same sample depths). When taken together, these assays suggest enhanced anaerobic digestion efficiency from foaming barns, as well as the possible accumulation of a surfactant at the manure-air interface of foaming deep pits. Overall, this work supports a three-phase system conceptualization of foam production in swine manure deep pits, and that the control of one or more of these phases will be required for mitigation

Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer

Inhibidores de la aromatasa; Terapia de progestinaAromatase inhibitors; Progestin therapyInhibidors de l'aromatasa; Teràpia amb progestinaBackground Approximately 20% of women with endometrial cancer have advanced-stage disease or suffer from a recurrence. For these women, prognosis is poor, and palliative treatment options include hormonal therapy and chemotherapy. Lack of predictive biomarkers and suboptimal use of existing markers for response to hormonal therapy have resulted in overall limited efficacy. Objective This study aimed to improve the efficacy of hormonal therapy by relating immunohistochemical expression of estrogen and progesterone receptors and estrogen receptor pathway activity scores to response to hormonal therapy. Study Design Patients with advanced or recurrent endometrial cancer and available biopsies taken before the start of hormonal therapy were identified in 16 centers within the European Network for Individualized Treatment in Endometrial Cancer and the Dutch Gynecologic Oncology Group. Tumor tissue was analyzed for estrogen and progesterone receptor expressions and estrogen receptor pathway activity using a quantitative polymerase chain reaction–based messenger RNA model to measure the activity of estrogen receptor–related target genes in tumor RNA. The primary endpoint was response rate defined as complete and partial response using the Response Evaluation Criteria in Solid Tumors. The secondary endpoints were clinical benefit rate and progression-free survival. Results Pretreatment biopsies with sufficient endometrial cancer tissue and complete response evaluation were available in 81 of 105 eligible cases. Here, 22 of 81 patients (27.2%) with a response had estrogen and progesterone receptor expressions of >50%, resulting in a response rate of 32.3% (95% confidence interval, 20.9–43.7) for an estrogen receptor expression of >50% and 50.0% (95% confidence interval, 35.2–64.8) for a progesterone receptor expression of >50%. Clinical benefit rate was 56.9% for an estrogen receptor expression of >50% (95% confidence interval, 44.9–68.9) and 75.0% (95% confidence interval, 62.2–87.8) for a progesterone receptor expression of >50%. The application of the estrogen receptor pathway test to cases with a progesterone receptor expression of >50% resulted in a response rate of 57.6% (95% confidence interval, 42.1–73.1). After 2 years of follow-up, 34.3% of cases (95% confidence interval, 20–48) with a progesterone receptor expression of >50% and 35.8% of cases (95% confidence interval, 20–52) with an estrogen receptor pathway activity score of >15 had not progressed. Conclusion The prediction of response to hormonal treatment in endometrial cancer improves substantially with a 50% cutoff level for progesterone receptor immunohistochemical expression and by applying a sequential test algorithm using progesterone receptor immunohistochemical expression and estrogen receptor pathway activity scores. However, results need to be validated in the prospective Prediction of Response to Hormonal Therapy in Advanced and Recurrent Endometrial Cancer (PROMOTE) study

Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer

Endometrial carcinoma; Immunohistochemistry; OutcomeCarcinoma de endometrio; Inmunohistoquímica; ResultadoCarcinoma d'endometri; Immunohistoquímica; ResultatObjective Pre-operative immunohistochemical (IHC) biomarkers are not incorporated in endometrial cancer (EC) risk classification. We aim to investigate the added prognostic relevance of IHC biomarkers to the ESMO-ESGO-ESTRO risk classification and lymph node (LN) status in EC. Methods Retrospective multicenter study within the European Network for Individualized Treatment of Endometrial Cancer (ENITEC), analyzing pre-operative IHC expression of p53, L1 cell-adhesion molecule (L1CAM), estrogen receptor (ER) and progesterone receptor (PR), and relate to ESMO-ESGO-ESTRO risk groups, LN status and outcome. Results A total of 763 EC patients were included with a median follow-up of 5.5-years. Abnormal IHC expression was present for p53 in 112 (14.7%), L1CAM in 79 (10.4%), ER- in 76 (10.0%), and PR- in 138 (18.1%) patients. Abnormal expression of p53/L1CAM/ER/PR was significantly related with higher risk classification groups, and combined associated with the worst outcome within the ‘high and advanced/metastatic’ risk group. In multivariate analysis p53-abn, ER/PR- and ESMO-ESGO-ESTRO ‘high and advanced/metastatic’ were independently associated with reduced disease-specific survival (DSS). Patients with abnormal IHC expression and lymph node metastasis (LNM) had the worst outcome. Patients with LNM and normal IHC expression had comparable outcome with patients without LNM and abnormal IHC expression. Conclusion The use of pre-operative IHC biomarkers has important prognostic relevance in addition to the ESMO-ESGO-ESTRO risk classification and in addition to LN status. For daily clinical practice, p53/L1CAM/ER/PR expression could serve as indicator for surgical staging and refine selective adjuvant treatment by incorporation into the ESMO-ESGO-ESTRO risk classification

Subgroup deliberation and voting

We consider three mechanisms for the aggregation of information in heterogeneous committees voting by Unanimity rule: Private Voting and voting preceded by either Plenary or Subgroup Deliberation. While the first deliberation protocol imposes public communication, the second restricts communication to homogeneous subgroups. We find that both protocols allow to Pareto improve on outcomes achieved under private voting. Furthermore, we find that when focusing on simple equilibria under Plenary Deliberation, Subgroup Deliberation Pareto improves on outcomes achieved under Plenary Deliberation

Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer

ObjectivePre-operative immunohistochemical (IHC) biomarkers are not incorporated in endometrial cancer (EC) risk classification. We aim to investigate the added prognostic relevance of IHC biomarkers to the ESMO-ESGO-ESTRO risk classification and lymph node (LN) status in EC.MethodsRetrospective multicenter study within the European Network for Individualized Treatment of Endometrial Cancer (ENITEC), analyzing pre-operative IHC expression of p53, L1 cell-adhesion molecule (L1CAM), estrogen receptor (ER) and progesterone receptor (PR), and relate to ESMO-ESGO-ESTRO risk groups, LN status and outcome.ResultsA total of 763 EC patients were included with a median follow-up of 5.5-years. Abnormal IHC expression was present for p53 in 112 (14.7%), L1CAM in 79 (10.4%), ER- in 76 (10.0%), and PR- in 138 (18.1%) patients. Abnormal expression of p53/L1CAM/ER/PR was significantly related with higher risk classification groups, and combined associated with the worst outcome within the ‘high and advanced/metastatic’ risk group. In multivariate analysis p53-abn, ER/PR- and ESMO-ESGO-ESTRO ‘high and advanced/metastatic’ were independently associated with reduced disease-specific survival (DSS). Patients with abnormal IHC expression and lymph node metastasis (LNM) had the worst outcome. Patients with LNM and normal IHC expression had comparable outcome with patients without LNM and abnormal IHC expression.ConclusionThe use of pre-operative IHC biomarkers has important prognostic relevance in addition to the ESMO-ESGO-ESTRO risk classification and in addition to LN status. For daily clinical practice, p53/L1CAM/ER/PR expression could serve as indicator for surgical staging and refine selective adjuvant treatment by incorporation into the ESMO-ESGO-ESTRO risk classification.</p